|[March 25, 2014]
NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration
STOCKHOLM --(Business Wire)--
NeuroVive Pharmaceutical AB (publ) (STO:NVP) and A1M Pharma AB (publ)
have announced that the two companies are initiating a research
collaboration in mitochondrial medicine. The partnership is governed by
a collaboration agreement signed on 21 March 2014.
· Initially, the purpose of the collaboration is to utilize the
companies' complementary scientific platforms within the framework of
ongoing research projects. The companies will evaluate results achieved
to date, then explore the potential for a closer collaboration focusing
on bringing products to market in a time-efficient manner.
· The costs related to the research collaboration will be covered by
each company separately and within budgeted development projects.
· Both companies will retain exclusive ownership rights to existing
registered intellectual property. However, any inventions arising from
the collaboration will be jointly owned by NeuroVive and A1M Pharma.
"I'm delighted to be able to announce this collaboration with A1M
Pharma, which will give both parties access to a broader scientific
platform in mitochondrial medicine. The companies' adjacent research
areas and strong R&D backgrounds, combined with their geographical
proximity, will secure a smooth integration of existing research
projects," commented NeuroVive's CEO Mikael Brönnegård.
"The collaboration will improve the potential for both parties to
conduct leading research in mitochondrial medicine. I'm convinced that
our experience and scientific backgrounds will generate new approaches
and increase the potential to create leading products with substantial
market potential. However, I would like to emphasize that we're
retaining our focu on pre-eclampsia and renal failure," responded A1M
Pharma's CEO Tomas Eriksson.
About A1M Pharma
A1M Pharma AB (publ) was founded by researchers at the University of
Lund, Sweden. The company was incorporated in 2008 with its main focus
on the development and commercialization of diagnostics and treatment of
pre-eclampsia. Pharmaceuticals development is based on A1M, a protein
that protects the body from toxic substances formed in oxidative stress,
and repairs damaged tissue. Diagnostics are based on the detection of
raised levels of the biomarker fetal hemoglobin in the mother's blood.
The researchers have developed a new method for discovering pregnancies
at risk of developing pre-eclampsia at an early stage. In 2013, the
company decided to complement its research to include pharmaceuticals
development focusing on renal failure, as recently completed studies
indicate that A1M protects renal tissue. A1M Pharma's shares are traded
on the AktieTorget marketplace under the ticker symbol A1M.
About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine
company, is developing a portfolio of products to treat acute
cardiovascular and neurological conditions through mitochondrial
protection. These medical conditions are characterized by a pressing
medical need and have no approved pharmaceutical treatment options at
present. NeuroVive's products CicloMulsion® (heart attack) and
NeuroSTAT® (traumatic brain injury) are currently being evaluated in
phase III and phase II studies, respectively. NeuroVive's research
programs also include products for the treatment of anti-viral
indications (Hepatitis B/C), brain cell injury in stroke patients, and
drug candidates for cellular protection and treating
mitochondria-related energy regulation diseases. NeuroVive's shares are
listed on NASDAQ OMX, Stockholm, Sweden.
NeuroVive Pharmaceutical AB
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
A1M Pharma AB Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 286 50 30 (switchboard)
NeuroVive Pharmaceutical AB (publ) is required to publish the
information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on 25 March 2014, at
8:30 a.m. CET.
This information was brought to you by Cision http://news.cision.com
[ Back To Cloud Computing 's Homepage ]